RxDoctor Payments DataLook up a doctor →

Jeremy Nivens, NP

Nurse Practitioner · Greenwood, INNPI 1780896431

Payments from drug & device makers

$12,378in general payments, 2019–2025

Across 775 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$3K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • Novartis$907
  • Incyte Corporation$692
  • Regeneron Healthcare Solutions, Inc.$684
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$12,04397%
  • Education$3353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,378 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$326,021
Medicare patients
1,466
Services billed
6,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab15$132,475
OtezlaApremilast21$105,608
Dupixent PenDupilumab25$92,433
Humira(Cf)Adalimumab13$92,071
Humira(Cf) PenAdalimumab13$90,386
Taltz AutoinjectorIxekizumab12$81,560
Dupixent SyringeDupilumab12$42,696
Clobetasol Propionate288$12,999
Triamcinolone Acetonide452$6,226
Ketoconazole284$3,776
Clindamycin Phosphate86$3,020
Fluorouracil25$2,355
Doxycycline Hyclate43$1,463
ValacyclovirValacyclovir Hcl21$1,453
Cephalexin88$1,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$412$105,60821 claims
AbbVieHumira(Cf)$2,055$92,07113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →